OVID THERAPEUTICS INC

Ovid’s new CFO, Carter Ross, buys 50,000 RSUs at $2.73 each—showing insider confidence and a long‑term stake in the company’s rare‑neurological therapeutics pipeline.

Ovid Therapeutics’ latest RSU grant to board member Stelios Papadopoulos signals insider confidence amid strong KCC2 clinical progress and an upcoming FDA IND filing, potentially boosting investor sentiment and stock momentum.